Tomoki Nakamizo

Dr. Tomoki Nakamizo

orcid

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2001 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
TKTakeshi Kihara
Takeshi Kihara
SSShun Shimohama
Shun Shimohama
HSHideyuki Sawada
Hideyuki Sawada
KHKazuhiro Honda
Kazuhiro Honda
TNTomoki Nakamizo
Tomoki Nakamizo
AAAkinori Akaike
Akinori Akaike
Multiple lines of evidence, from molecular and cellular to epidemiological, have implicated nicotinic transmission in the pathogenesis of Alzheimer's disease (AD). Here we show the signal transduction mechanism involved in nicotinic receptor-mediated protection against β-amyloid-enhanced glutamate neurotoxicity. Nicotine-induced protection was suppressed by an α7 nicotinic receptor antagonist (α-bungarotoxin), a phosphatidylinositol 3-kinase (PI3K) inhibitor (LY294002 and wortmannin), and a Src inhibitor (PP2). Levels of phosphorylated Akt, an effector of PI3K, and Bcl-2 were increased by nicotine. The α7 nicotinic receptor was physically associated with the PI3K p85 subunit and Fyn. These findings indicate that the α7 nicotinic receptor transduces signals to PI3K in a cascade, which ultimately contributes to a neuroprotective effect. This might form the basis of a new treatment for AD.

30 May 2001 in Journal of Neuroscience Research
Verified
Journal Article
Closed access
PDF file
KHKazuhiro Honda
Kazuhiro Honda
SSShun Shimohama
Shun Shimohama
HSHideyuki Sawada
Hideyuki Sawada
TKTakeshi Kihara
Takeshi Kihara
TNTomoki Nakamizo
Tomoki Nakamizo
AAAkinori Akaike
Akinori Akaike

1 December 2004 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
TKTakeshi Kihara
Takeshi Kihara
HSHideyuki Sawada
Hideyuki Sawada
TNTomoki Nakamizo
Tomoki Nakamizo
RKRie Kanki
Rie Kanki
HYHirofumi Yamashita
Hirofumi Yamashita
SSShun Shimohama
Shun Shimohama

1 March 2004 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
HSHideyuki Sawada
Hideyuki Sawada
RKRyuichi Kohno
Ryuichi Kohno
TKTakeshi Kihara
Takeshi Kihara
YIYasuhiko Izumi
Yasuhiko Izumi
NSNoriko Sakka
Noriko Sakka
SSShun Shimohama
Shun Shimohama
Parkinson's disease is characterized by dopaminergic neuronal death and the presence of Lewy bodies. α-Synuclein is a major component of Lewy bodies, but the process of its accumulation and its relationship to dopaminergic neuronal death has not been resolved. Although the pathogenesis has not been clarified, mitochondrial complex I is suppressed, and caspase-3 is activated in the affected midbrain. Here we report that a combination of 1-methyl-4-phenylpyridinium ion (MPP+) or rotenone and proteasome inhibition causes the appearance of α-synuclein-positive inclusion bodies. Unexpectedly, however, proteasome inhibition blocked MPP+- or rotenone-induced dopaminergic neuronal death. MPP+ elevated proteasome activity, dephosphorylated mitogen-activating protein kinase (MAPK), and activated caspase-3. Proteasome inhibition reversed the MAPK dephosphorylation and blocked caspase-3 activation; the neuroprotection was blocked by a p42 and p44 MAPK kinase inhibitor. Thus, the proteasome plays an important role in both inclusion body formation and dopaminergic neuronal death but these processes form opposite sides on the proteasome regulation in this model.

12 February 2001 in Journal of Neuroscience Research
Verified
Journal Article
Closed access
MUMakoto Urushitani
Makoto Urushitani
TOTomoki
Tomoki
TNTomoki Nakamizo
Tomoki Nakamizo
RIRyotaku Inoue
Ryotaku Inoue
HSHideyuki Sawada
Hideyuki Sawada
SSShun Shimohama
Shun Shimohama

1 June 2002 in Neuropharmacology
Verified
Journal Article
Closed access
HSHideyuki Sawada
Hideyuki Sawada
MIMasakazu Ibi
Masakazu Ibi
TKTakeshi Kihara
Takeshi Kihara
KHKazuhiro Honda
Kazuhiro Honda
TNTomoki Nakamizo
Tomoki Nakamizo
SSShun Shimohama
Shun Shimohama